## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.6% below STRENGTH zone (4.0-10.0%); PEG 4.02 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-12.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($155.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Looking Into Jazz Pharmaceuticals PLC's Recent Short Interest**
- Source: Sahm | 20251203T041259 | Somewhat-Bearish | Relevance: 100%
- Jazz Pharmaceuticals PLC (NYSE: JAZZ) has experienced a 9.01% increase in short interest since its last report, with 5.12 million shares sold short, representing 9.56% of its float. This rise in short interest suggests a more bearish market sentiment towards the company, as its short interest percentage is also higher than most of its peers, whose average is 3.25%.

**2. Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium**
- Source: PR Newswire | 20251201T090918 | Bullish | Relevance: 100%
- Jazz Pharmaceuticals announced that pivotal Phase 3 results for Ziihera® (zanidatamab-hrii) in HER2-positive gastroesophageal adenocarcinoma (GEA), along with new overall survival analysis for previously treated HER2-positive biliary tract cancer, will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. The HERIZON-GEA-01 trial demonstrated significant improvements in progression-free survival and overall survival for Ziihera combinations. These presentations underscore the expanding clinical profile of zanidatamab and its potential to become a new standard of care for HER2-driven gastrointestinal cancers.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | UBS | $188 | $163 | +15% |
| 2025-11-18 | Wells Fargo | $235 | $170 | +38% |
| 2025-11-18 | Baird | $209 | $160 | +31% |
| 2025-11-18 | B of A Securiti | $247 | $230 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | UBS | down | Neutral |
| 2025-11-18 | Wells Fargo | main | Overweight |
| 2025-11-18 | Baird | main | Outperform |
| 2025-11-18 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 13 ($5.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-12.0% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Valuation stretched: PEG 4.0x requires aggressive growth execution.
4. Elevated short interest (9.6%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 7 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.02 signals overvaluation risk, limited margin of safety. Forward P/E 7.4x attractive for 179% earnings growth. Analyst sentiment positive (7 raises, avg +19%). Insider selling cluster ($5.3M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.4B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.02 |
| Forward P/E | 7.4 |
| Current P/E | 20.6 |
| YoY Growth | 179.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 14.7% to 2.6% (-12.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.4pp (needs >4.0% for momentum thesis). MRS_5 (-3.2%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.7% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.63% (CS: 74) | Neutral |
| RSI_14 | 59.9 | Neutral |
| MACD Histogram | -0.43 | Bearish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.150x | Above |
| vs SMA200 | 1.337x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $167.10
- **Stop Loss:** $155.12 (7.2% risk)
- **Target:** $179.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 79
- **Position Value:** $13,200.90
- **Portfolio %:** 13.20%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*